The next-generation sequencing (ngs) in precision medicine market size has grown rapidly in recent years. It will grow from $6.42 billion in 2025 to $7.52 billion in 2026 at a compound annual growth rate (CAGR) of 17.2%. The growth in the historic period can be attributed to development of high-throughput sequencers, rising awareness of personalized medicine, growth in genomic research, expansion of bioinformatics software, adoption of precision medicine in clinical trials.
The next-generation sequencing (ngs) in precision medicine market size is expected to see rapid growth in the next few years. It will grow to $14.05 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to technological advancements in sequencing instruments, integration of ai in genomics, growth in cloud-based sequencing services, increasing collaborations between pharma and biotech companies, expansion of precision medicine in emerging regions. Major trends in the forecast period include AI-powered genomic analysis, cloud-based sequencing solutions, personalized medicine expansion, automation in sequencing workflows, real-time genomic data interpretation.
The increasing incidence of genetic disorders is expected to drive the growth of the next-generation sequencing (NGS) market in precision medicine. Genetic disorders are conditions caused by abnormalities in an individual's DNA, which can be inherited or result from mutations. Advances in diagnostic technologies, such as genetic screening and next-generation sequencing, have improved the ability to detect genetic disorders, leading to a higher reported prevalence. NGS plays a vital role in precision medicine by identifying genetic mutations, enabling accurate diagnoses, personalized treatments, and early interventions. For example, in May 2024, the National Health Service in the UK reported that around 17,000 people in England live with sickle cell disease, a genetic blood disorder, with approximately 250 new cases diagnosed annually. As the incidence of genetic disorders continues to rise, the demand for NGS in precision medicine is increasing.
Companies operating in the NGS precision medicine market are focusing on innovative solutions, such as multimodal DNA and RNA library kits, to improve the efficiency and accuracy of genomic analyses. These kits enable the simultaneous preparation of sequencing libraries from both DNA and RNA within a single workflow, allowing for comprehensive analysis of a sample’s genome and transcriptome. For instance, in May 2024, Qiagen N.V., a Germany-based provider of sample and assay technologies, launched the QIAseq Multimodal DNA and RNA Library Kit. This NGS solution supports multiomic studies by streamlining DNA and RNA library preparation from a single sample, reducing the need for large amounts of material and labor-intensive procedures associated with traditional separate workflows. By enhancing the efficiency of multiomic research, this kit supports precision medicine advancements, particularly in cancer research, by facilitating better biomarker discovery and disease understanding.
In June 2025, Qiagen N.V. partnered with Incyte Corporation, a U.S.-based biopharmaceutical company, to develop a multimodal NGS companion diagnostic panel for patients with myeloproliferative neoplasms (MPNs). This collaboration aims to create a diagnostic tool that identifies mutations in CALR and other genes associated with MPNs, helping guide patient selection for targeted therapies and improving treatment outcomes. By advancing precision medicine, this partnership supports the development of more effective treatments for MPN patients.
Major companies operating in the next-generation sequencing (ngs) in precision medicine market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Natera Inc., Tempus Labs Inc., 10x Genomics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Fulgent Genetics Inc., Twist Bioscience Corporation, Pacific Biosciences of California Inc., Macrogen Inc., Ultima Genomics Inc., Personalis Inc., Element Biosciences Inc., Genomenon Inc., Strand Life Sciences Pvt. Ltd., Singular Genomics Systems Inc.
North America was the largest region in the next-generation sequencing (NGS) in precision medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing (ngs) in precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation sequencing (ngs) in precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the NGS in precision medicine market by increasing costs for imported sequencing instruments, consumables, and bioinformatics tools. Hospitals, academic institutions, and biopharmaceutical companies are most affected, particularly in Asia-Pacific and Europe. Segments like high-throughput sequencers and DNA library kits face higher cost pressures. However, tariffs are encouraging local production and domestic R&D investments, which may improve long-term accessibility and innovation.
The next-generation sequencing (ngs) in precision medicine market research report is one of a series of new reports that provides next-generation sequencing (ngs) in precision medicine market statistics, including next-generation sequencing (ngs) in precision medicine industry global market size, regional shares, competitors with a next-generation sequencing (ngs) in precision medicine market share, detailed next-generation sequencing (ngs) in precision medicine market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing (ngs) in precision medicine industry. This next-generation sequencing (ngs) in precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Next-generation sequencing (NGS) in precision medicine refers to a cutting-edge genomic technology that allows rapid and comprehensive analysis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequences at exceptional scale and speed, providing insights far beyond those offered by traditional sequencing approaches. It plays a central role in precision medicine by revealing detailed information on individual genetic variations and molecular profiles, supporting highly informed medical assessments and decisions.
The primary types of products and services in next-generation sequencing (NGS) in precision medicine include sequencing instruments, consumables and reagents, library preparation kits, bioinformatics software, and NGS services. Sequencing instruments are specialized devices used to decode the DNA or RNA sequences of biological samples. Technologies covered include whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, RNA sequencing, and single-cell sequencing. NGS is applied in fields such as oncology, infectious diseases, rare and inherited disorders, prenatal and reproductive health, and pharmacogenomics. Key end users include hospitals and clinics, academic and research institutions, biopharmaceutical companies, diagnostic laboratories, and contract research organizations (CROs).
The next-generation sequencing (NGS) in precision medicine market consists of revenues earned by entities by providing services such as whole genome sequencing, metagenomic sequencing, hereditary cancer screening, pharmacogenomics testing, and rare disease diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation sequencing (NGS) in precision medicine market also includes sales of sequencing instruments, reagents and consumables, bioinformatics software, data analysis tools, and sequencing panels and assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The next-generation sequencing (ngs) in precision medicine market size is expected to see rapid growth in the next few years. It will grow to $14.05 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to technological advancements in sequencing instruments, integration of ai in genomics, growth in cloud-based sequencing services, increasing collaborations between pharma and biotech companies, expansion of precision medicine in emerging regions. Major trends in the forecast period include AI-powered genomic analysis, cloud-based sequencing solutions, personalized medicine expansion, automation in sequencing workflows, real-time genomic data interpretation.
The increasing incidence of genetic disorders is expected to drive the growth of the next-generation sequencing (NGS) market in precision medicine. Genetic disorders are conditions caused by abnormalities in an individual's DNA, which can be inherited or result from mutations. Advances in diagnostic technologies, such as genetic screening and next-generation sequencing, have improved the ability to detect genetic disorders, leading to a higher reported prevalence. NGS plays a vital role in precision medicine by identifying genetic mutations, enabling accurate diagnoses, personalized treatments, and early interventions. For example, in May 2024, the National Health Service in the UK reported that around 17,000 people in England live with sickle cell disease, a genetic blood disorder, with approximately 250 new cases diagnosed annually. As the incidence of genetic disorders continues to rise, the demand for NGS in precision medicine is increasing.
Companies operating in the NGS precision medicine market are focusing on innovative solutions, such as multimodal DNA and RNA library kits, to improve the efficiency and accuracy of genomic analyses. These kits enable the simultaneous preparation of sequencing libraries from both DNA and RNA within a single workflow, allowing for comprehensive analysis of a sample’s genome and transcriptome. For instance, in May 2024, Qiagen N.V., a Germany-based provider of sample and assay technologies, launched the QIAseq Multimodal DNA and RNA Library Kit. This NGS solution supports multiomic studies by streamlining DNA and RNA library preparation from a single sample, reducing the need for large amounts of material and labor-intensive procedures associated with traditional separate workflows. By enhancing the efficiency of multiomic research, this kit supports precision medicine advancements, particularly in cancer research, by facilitating better biomarker discovery and disease understanding.
In June 2025, Qiagen N.V. partnered with Incyte Corporation, a U.S.-based biopharmaceutical company, to develop a multimodal NGS companion diagnostic panel for patients with myeloproliferative neoplasms (MPNs). This collaboration aims to create a diagnostic tool that identifies mutations in CALR and other genes associated with MPNs, helping guide patient selection for targeted therapies and improving treatment outcomes. By advancing precision medicine, this partnership supports the development of more effective treatments for MPN patients.
Major companies operating in the next-generation sequencing (ngs) in precision medicine market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Natera Inc., Tempus Labs Inc., 10x Genomics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Fulgent Genetics Inc., Twist Bioscience Corporation, Pacific Biosciences of California Inc., Macrogen Inc., Ultima Genomics Inc., Personalis Inc., Element Biosciences Inc., Genomenon Inc., Strand Life Sciences Pvt. Ltd., Singular Genomics Systems Inc.
North America was the largest region in the next-generation sequencing (NGS) in precision medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation sequencing (ngs) in precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation sequencing (ngs) in precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the NGS in precision medicine market by increasing costs for imported sequencing instruments, consumables, and bioinformatics tools. Hospitals, academic institutions, and biopharmaceutical companies are most affected, particularly in Asia-Pacific and Europe. Segments like high-throughput sequencers and DNA library kits face higher cost pressures. However, tariffs are encouraging local production and domestic R&D investments, which may improve long-term accessibility and innovation.
The next-generation sequencing (ngs) in precision medicine market research report is one of a series of new reports that provides next-generation sequencing (ngs) in precision medicine market statistics, including next-generation sequencing (ngs) in precision medicine industry global market size, regional shares, competitors with a next-generation sequencing (ngs) in precision medicine market share, detailed next-generation sequencing (ngs) in precision medicine market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing (ngs) in precision medicine industry. This next-generation sequencing (ngs) in precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Next-generation sequencing (NGS) in precision medicine refers to a cutting-edge genomic technology that allows rapid and comprehensive analysis of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequences at exceptional scale and speed, providing insights far beyond those offered by traditional sequencing approaches. It plays a central role in precision medicine by revealing detailed information on individual genetic variations and molecular profiles, supporting highly informed medical assessments and decisions.
The primary types of products and services in next-generation sequencing (NGS) in precision medicine include sequencing instruments, consumables and reagents, library preparation kits, bioinformatics software, and NGS services. Sequencing instruments are specialized devices used to decode the DNA or RNA sequences of biological samples. Technologies covered include whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, RNA sequencing, and single-cell sequencing. NGS is applied in fields such as oncology, infectious diseases, rare and inherited disorders, prenatal and reproductive health, and pharmacogenomics. Key end users include hospitals and clinics, academic and research institutions, biopharmaceutical companies, diagnostic laboratories, and contract research organizations (CROs).
The next-generation sequencing (NGS) in precision medicine market consists of revenues earned by entities by providing services such as whole genome sequencing, metagenomic sequencing, hereditary cancer screening, pharmacogenomics testing, and rare disease diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation sequencing (NGS) in precision medicine market also includes sales of sequencing instruments, reagents and consumables, bioinformatics software, data analysis tools, and sequencing panels and assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Next-Generation Sequencing (Ngs) in Precision Medicine Market Characteristics
3. Next-Generation Sequencing (Ngs) in Precision Medicine Market Supply Chain Analysis
4. Global Next-Generation Sequencing (Ngs) in Precision Medicine Market Trends and Strategies
5. Next-Generation Sequencing (Ngs) in Precision Medicine Market Analysis of End Use Industries
7. Global Next-Generation Sequencing (Ngs) in Precision Medicine Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Next-Generation Sequencing (Ngs) in Precision Medicine Total Addressable Market (TAM) Analysis for the Market
9. Next-Generation Sequencing (Ngs) in Precision Medicine Market Segmentation
10. Next-Generation Sequencing (Ngs) in Precision Medicine Market Regional and Country Analysis
11. Asia-Pacific Next-Generation Sequencing (Ngs) in Precision Medicine Market
12. China Next-Generation Sequencing (Ngs) in Precision Medicine Market
13. India Next-Generation Sequencing (Ngs) in Precision Medicine Market
14. Japan Next-Generation Sequencing (Ngs) in Precision Medicine Market
15. Australia Next-Generation Sequencing (Ngs) in Precision Medicine Market
16. Indonesia Next-Generation Sequencing (Ngs) in Precision Medicine Market
17. South Korea Next-Generation Sequencing (Ngs) in Precision Medicine Market
18. Taiwan Next-Generation Sequencing (Ngs) in Precision Medicine Market
19. South East Asia Next-Generation Sequencing (Ngs) in Precision Medicine Market
20. Western Europe Next-Generation Sequencing (Ngs) in Precision Medicine Market
21. UK Next-Generation Sequencing (Ngs) in Precision Medicine Market
22. Germany Next-Generation Sequencing (Ngs) in Precision Medicine Market
23. France Next-Generation Sequencing (Ngs) in Precision Medicine Market
24. Italy Next-Generation Sequencing (Ngs) in Precision Medicine Market
25. Spain Next-Generation Sequencing (Ngs) in Precision Medicine Market
26. Eastern Europe Next-Generation Sequencing (Ngs) in Precision Medicine Market
27. Russia Next-Generation Sequencing (Ngs) in Precision Medicine Market
28. North America Next-Generation Sequencing (Ngs) in Precision Medicine Market
29. USA Next-Generation Sequencing (Ngs) in Precision Medicine Market
30. Canada Next-Generation Sequencing (Ngs) in Precision Medicine Market
31. South America Next-Generation Sequencing (Ngs) in Precision Medicine Market
32. Brazil Next-Generation Sequencing (Ngs) in Precision Medicine Market
33. Middle East Next-Generation Sequencing (Ngs) in Precision Medicine Market
34. Africa Next-Generation Sequencing (Ngs) in Precision Medicine Market
36. Next-Generation Sequencing (Ngs) in Precision Medicine Market Competitive Landscape and Company Profiles
37. Next-Generation Sequencing (Ngs) in Precision Medicine Market Other Major and Innovative Companies
40. Next-Generation Sequencing (Ngs) in Precision Medicine Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Next-Generation Sequencing (NGS) In Precision Medicine Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses next-generation sequencing (ngs) in precision medicine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for next-generation sequencing (ngs) in precision medicine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next-generation sequencing (ngs) in precision medicine market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product And Service: Sequencing Instruments; Consumables And Reagents; Library Preparation Kits; Bioinformatics Software; Next-Generation Sequencing (NGS) Services2) By Technology: Whole Genome Sequencing (WGS); Whole Exome Sequencing (Wes); Targeted Sequencing; Ribonucleic Acid (RNA) Sequencing; Single-Cell Sequencing
3) By Application: Oncology; Infectious Disease; Rare And Inherited Disorders; Prenatal And Reproductive Health; Pharmacogenomics
4) By End Use: Hospitals And Clinics; Academic And Research Institutions; Biopharmaceutical Companies; Diagnostic Laboratories; Contract Research Organizations (CROs)
Subsegments:
1) By Sequencing Instruments: Benchtop Sequencers; High Throughput Sequencers2) By Consumables And Reagents: Sequencing Reagents; Sequencing Chips; Flow Cells; Sample Preparation Reagents
3) By Library Preparation Kits: Deoxyribonucleic Acid (DNA) Library Preparation Kits; Ribonucleic Acid (RNA) Library Preparation Kits; Whole Genome Amplification Kits; Target Enrichment Kits
4) By Bioinformatics Software: Data Analysis Software; Data Management Software; Sequence Alignment Software; Variant Calling Software
5) By Next-Generation Sequencing Services: Whole Genome Sequencing Services; Whole Exome Sequencing Services; Targeted Sequencing Services; Ribonucleic Acid (RNA) Sequencing Services; Epigenomic Sequencing Services
Companies Mentioned: Thermo Fisher Scientific Inc.; Eurofins Scientific SE; Agilent Technologies Inc.; Illumina Inc.; Bio-Rad Laboratories Inc.; Exact Sciences Corporation; QIAGEN N.V.; Natera Inc.; Tempus Labs Inc.; 10x Genomics Inc.; BGI Genomics Co. Ltd.; Guardant Health Inc.; Caris Life Sciences Inc.; Fulgent Genetics Inc.; Twist Bioscience Corporation; Pacific Biosciences of California Inc.; Macrogen Inc.; Ultima Genomics Inc.; Personalis Inc.; Element Biosciences Inc.; Genomenon Inc.; Strand Life Sciences Pvt. Ltd.; Singular Genomics Systems Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Next-Generation Sequencing (NGS) in Precision Medicine market report include:- Thermo Fisher Scientific Inc.
- Eurofins Scientific SE
- Agilent Technologies Inc.
- Illumina Inc.
- Bio-Rad Laboratories Inc.
- Exact Sciences Corporation
- QIAGEN N.V.
- Natera Inc.
- Tempus Labs Inc.
- 10x Genomics Inc.
- BGI Genomics Co. Ltd.
- Guardant Health Inc.
- Caris Life Sciences Inc.
- Fulgent Genetics Inc.
- Twist Bioscience Corporation
- Pacific Biosciences of California Inc.
- Macrogen Inc.
- Ultima Genomics Inc.
- Personalis Inc.
- Element Biosciences Inc.
- Genomenon Inc.
- Strand Life Sciences Pvt. Ltd.
- Singular Genomics Systems Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.52 Billion |
| Forecasted Market Value ( USD | $ 14.05 Billion |
| Compound Annual Growth Rate | 16.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
